Chronic prescription opioid use is common among a sizable minority of veterans with MS, according to a recent study.
Chronic pain, defined by the Centers for Disease Control and Prevention (CDC) as pain lasting longer than 3 months, is a prevalent symptom of multiple sclerosis (MS). In fact, 50% to 75% of people living with MS suffer from chronic pain. Pain can be neuropathic, stemming from nerve damage, or musculoskeletal due to muscle spasms and joint damage or stress.
Although opioids are often prescribed in the United States to treat chronic pain, the CDC’s 2022 Clinical Practice Guideline for Prescribing Opioids for Pain does not recommend their use as first-line therapy for chronic pain. There is limited evidence of their long-term effectiveness in alleviating chronic pain, and their prolonged use has been associated with a myriad of negative outcomes, including increased risk for opioid use disorder, unintentional overdose, falls that may lead to fractures and myocardial infarction.
Against this backdrop, a research team led by Aaron P. Turner, Ph.D. at the University of Washington in Seattle, sought to identify risk factors associated with chronic prescription opioid use in patients with MS. Turner and his colleagues conducted a retrospective longitudinal cohort study analyzing data obtained from the U.S. Department of Veterans Affairs of patients diagnosed with MS before 2017 and who received treatment at the Veteran’s Health Administration from 2015 to 2017. The study results were published earlier this month in the Archive of Physical Medicine and Rehabilitation.
A total of 14,974 participants with MS were included. The mean age was 58 years, 92% were non-Hispanic, 73.5% were White, 54.5% were married, and 66.7% lived in urban areas. Additionally, 62.2% had been diagnosed with a pain condition, and 39.3% had a history of depression.
Overall, prescription opioid use decreased from 2015 to 2017 (27.3% versus 22.9%). Chronic prescription opioid use (defined as lasting 90 days or longer) also declined during the three study years (14.6% versus 12.2%). However, the researchers found that over half of all annual prescription opioid use was identified as chronic.
The strongest risk factor for chronic opioid use was chronic prescription opioid use the previous year. Patients with chronic prescription opioid use in 2016 were almost 200 times more likely to have chronic opioid use in 2017 compared with participants without a history of chronic prescription opioid use. Other risk factors identified included living in rural areas, having a history of a pain condition, paraplegia or hemiplegia, and post-traumatic stress disorder. On the other hand, having a history of dementia and psychotic disorder reduced the risk of chronic prescription opioid use.
The study authors conclude, “Despite reductions over time, chronic prescription opioid use remains common among a substantial minority of veterans with MS and is associated with multiple biopsychosocial factors that are important for understanding risk for long-term use.” They added, “The prevalence and persistence of chronic use over time suggests education about long-term opioid use, review of non-pharmacologic treatment options, and discussion of a plan for opioid discontinuation should be reviewed with patients prior to initial prescription.”
This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.
Read More
Most Real-World Studies Report Positive Outcomes of Rituximab Use in Multiple Sclerosis
May 8th 2024Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Read More
Diabetes Weight Loss Drugs Could be Linked to Reduced Risk of MS, Study Finds
April 12th 2024Drug repurposing has recently emerged as an attractive pathway for developing new treatments due to its relatively fast and cost-efficient trajectory. Because obesity and MS share inflammatory properties, researchers used data from the FDA Adverse Event Reporting System to investigate the association between weight loss-inducing drugs and MS
Read More
Specialty Pharmacist Interventions Result in More Than $150,000 in Cost Avoidance For MS Patients
April 4th 2024Darina Georgieva, Pharm.D., and her colleagues from the department of pharmaceutical services at Vanderbilt University Medical Center, conducted a retrospective observational study to learn the costs avoided through specialty pharmacist interventions for patients at the Vanderbilt MS Clinic. The study results were published in the Journal of Managed Care and Specialty Pharmacy earlier this month.
Read More